Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. The diagnosis and treatment of aplastic anemia: a review

    ... or alternative immunosuppressive therapies, such as alemtuzumab , may represent valid tools for resistant/relapsing cases. New ...

    Research Article last updated 05/26/2015 - 10:30am.

  2. Aplastic Anemia: Alternative Immunosuppressive Treatments and Eltrombopag. A report from the 2014 EBMT Educational Meeting from the Severe Aplastic Anaemia and Infectious Diseases Working Parties

    ... other than h-ATG (rabbit-ATG, cyclophosphamide , alemtuzumab ) has not reproduced the positive outcome seen with standard ...

    Research Article last updated 03/02/2015 - 11:53am.

  3. Recent Developments in Drug Therapy for Aplastic Anemia

    ... for nonsevere AA (NAA); however, data is limited. Alemtuzumab or eltrombopag are options for relapsed AA in select patients. ... are needed before this is adopted into clinical practice. Alemtuzumab and eltrombopag have been studied for treatment of AA; recruiting ...

    Research Article last updated 09/24/2014 - 10:21am.

  4. Antibodies in the treatment of aplastic anemia.

    ... proposed and new antibodies have emerged: porcine ATG, alemtuzumab , daclizumab , and rituximab. Experience with these antibodies is limited to a few studies with alemtuzumab being the most promising, but the results are interesting and ...

    Research Article last updated 06/15/2012 - 3:06pm.

  5. Targeting immune dysregulation in myelodysplastic syndromes.

    ... After treatment with a clinical protocol using alemtuzumab , an anti-CD52 antibody, her blood cell counts returned to ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.

    ... all, 28/29 proceeded to transplant; 27 received ATG or alemtuzumab . Post HCT, 180 day non-relapse mortality (NRM) was 7% (95% ...

    Research Article last updated 06/28/2013 - 1:30pm.

  7. Management of the refractory aplastic anemia patient: what are the options?

    ... is only ∼ 30% to 35%. Response may also occur with alemtuzumab or the thrombopoietin mimetic eltrombopag in refractory AA. The ...

    Research Article last updated 01/07/2014 - 12:28pm.

  8. Management of the refractory aplastic anemia patient: what are the options?

    ... is only around 30-35%. Response may also occur with alemtuzumab or the thrombopoietin mimetic, eltrombopag, in refractory AA. ...

    Research Article last updated 09/26/2013 - 3:05pm.

  9. Aplastic anemia: therapeutic updates in immunosuppression and transplantation

    ... and cyclosporine . More recently, the role of alemtuzumab in SAA has been better defined and an oral thrombomimetic, ...

    Research Article last updated 01/02/2013 - 2:25pm.

  10. Immunological derangement in hypocellular myelodysplastic syndromes

    ... , anti-thymocyte globulin and/or cyclosporine, or alemtuzumab . Here we review all these immune mechanisms as well as the ...

    Research Article last updated 05/22/2014 - 9:53am.